The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...

Chemotherapy saves lives, but for early-stage breast cancer, it may sometimes do more harm than good. An oncologist explains ...

Novartis Canada applauds Canada's Drug Agency (CDA-AMC) for its positive draft recommendation to reimburse Kisqali® ...

The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.

Sacramento, California - January 16, 2026 - PRESSADVANTAGE - Silverback Digital Marketing has issued an announcement ...

Internal promotion strengthens Patriot’s sales leadership and reinforces a relationship-first approach to ISP and OSP ...

AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Oncologist warns that cancer treatments can damage heart health, particularly for those with existing cardiovascular risks, suggesting an integrated approach.

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's ...

Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b ...